The price has been high since the beginning of the year. Of the stock acquisition rights issued on 23/6/5, it was announced that 7877 (11.42% of the total number issued) were exercised, and 787,700 shares were issued. There are 15,910 unexercised stock acquisition rights. Concerns about future dilution of stock values have receded due to mass exercise. Also, it was reported that Qualypus ＜4894＞ will apply to the Ministry of Health, Labor, and Welfare for approval to manufacture and sale of myocardial sheets created from iPS cells in June, and it seems that investors' attention is being drawn to drug discovery ventures.
セルシード---年初来高値、新株予約権の大量行使で希薄化懸念後退、創薬ベンチャーに注目集まる
Cellseed --- year-to-date high prices, dilution concerns recede due to mass exercise of stock acquisition rights, and attention is drawn to drug discovery ventures
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.